Navigation Links
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
Date:10/17/2009

or equal to 0.001).

(+) Post hoc analysis of RAPID 1

The post hoc analysis of the RAPID 1 study aimed to determine if a more rapid response to certolizumab pegol, together with MTX, was associated with better long-term improvements in physical function, and relief of pain and fatigue, in the treatment of active RA in patients who did not respond to conventional treatment. Patients who responded to treatment with certolizumab pegol 200 mg every two weeks by Week 12 were divided into two subgroups: The earlier Week 6 responders and later Week 12 responders based on responder definitions: ACR20 response or DAS28 change of greater than or equal to 1.2 from baseline. The early Week 6 DAS and ACR20 responders had a higher probability of achieving ACR20/50/70 scores at Week 52 (p < 0.001). By ACR20 definition, 83.1% of the early Week 6 responders maintained an ACR20 response at Week 52 compared to 66.7% of the later Week 12 responders (p < 0.001).

(++) Open label extension study to RAPID 1(028)

The Phase III, open-label extension (OLE) study to RAPID 1 is investigating the long-term efficacy and safety of subcutaneous certolizumab pegol (400 mg every 2 weeks) together with methotrexate in the treatment of signs and symptoms and in the prevention of joint damage in patients with active RA. Patients completing RAPID 1 through 52 weeks (completers), or who were ACR20 nonresponders at Week 12 (confirmed at Week 14) and were to be withdrawn from the study at Week 16 (withdrawers), could continue in the 028 study. The open-label extension study continued to evaluate the effects of certolizumab pegol( )over two years. This analysis was performed in completers (n= 508) with 100 weeks of exposure from RAPID 1 baseline. 95.8% of completers entered open-label treatment, and of these, 91.1% continued in the study after 100 Weeks. ACR response rates in these patients
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
2. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
3. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
4. Tiny test tube experiment shows reaction of melting materials at the nano scale
5. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
6. Topical erectile dysfunction therapy shows promise
7. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
8. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
9. Video shows nanotube spins as it grows
10. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
11. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... Corporation (NASDAQ: NEOG ) announced today that its ... which ended Feb. 28, increased 13% to $7,454,000, when ... in the current quarter were $0.20, compared to $0.18 ... over prior year to $24,142,000, or $0.65 per share, ... same period a year ago. Revenues for ...
(Date:3/26/2015)... Houston, Texas (PRWEB) March 26, 2015 ... assist technologies, and Transonic, a supplier of precision transit-time ... board that will greatly improve the efficiency of the ... will enable LVAD patients to experience greater mobility and ... embedded with the miniature flow board, will draw 1/6th ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Pharmasset, Inc.,(Nasdaq: VRUS ) announced today that its ... Conference being held from September 24 - 27,2007 in ... Chief,Executive Officer, will provide an overview of the company ... To access a simultaneous webcast of the presentation via ...
... Studies Demonstrate Activity of ... Gram-Positive Bacteria, CHICAGO, Sept. 18 Astellas ... ) announced today results with the,investigational compound telavancin ... skin structure infections,(cSSSIs) from a controlled Phase 3 ...
... /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today announced additional ... 43rd Scientific Sessions of the European Association ... Phase II meal study data was disclosed ... and pharmacodynamics of,insulin VIAject(TM), insulin lispro and ...
Cached Biology Technology:Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 3Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 4Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 5Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 6Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... -- Beta Systems today announced Fast ... (IAM) solution for a fixed price and with ... IAM package, customers benefit from the 30 years, ... implementations across different industries. The new fixed-price IAM ... necessary services and consulting. It spans the implementation ...
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... Spanish . ,The oil spill from ... to the ecosystems in the Bay of Biscay. A PhD ... studied the consequences of this spill for the mussels inhabiting ... of the PhD thesis is the biologist Ms Larraitz Garmendia ...
... Norway MA Current research describes a new method ... onset of symptoms. The related report by Zangani et ... NF-κB activation reveals pathology in multiple organ systems," appears ... Journal of Pathology . Autoimmune diseases such as ...
... Germ cells, the cells which give rise to a ... rate of spontaneous point mutations than adult somatic cells, which ... organs. Despite their comparatively higher mutation rates, however, adult ... cloning process called somatic cell nuclear transfer (SCNT). This ...
Cached Biology News:The Prestige oil spill caused changes in the cell structure of mussels 2Stopping autoimmunity before it strikes 2Therapeutic cloning gets a boost with new research findings 2
... Spacer Leu-CMK FLISP Assay with FAM-Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
Request Info...
... tool provides the firm pressure necessary ... in tubes or plates. The multifunctional ... that firmly holds thin-wall 0.5 ml ... opening or closing. A side slot ...
... microbial system, 100 to 240 V, ... of bacterial and fungal cells. This ... module for exponential decay delivery, ShockPod ... each of 0.1 and 0.2 cm ...
Biology Products: